Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2017 15:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Resignation of Chief Financial Officer

TORONTO, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
July 31, 2017 08:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported Class Action Lawsuit

TORONTO, July 31, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
July 26, 2017 20:15 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista™ (oxycodone hydrochloride extended release), an Abuse-Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

TORONTO, July 26, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
July 11, 2017 17:15 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Second Quarter 2017 Results

TORONTO, July 11, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
June 30, 2017 16:05 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

TORONTO, June 30, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
June 06, 2017 08:50 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Launch of Generic Seroquel XR® by Mallinckrodt

TORONTO, June 06, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
May 26, 2017 17:40 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Replace Expiring Shelf Registration Statement

TORONTO, May 26, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
May 24, 2017 16:05 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical

TORONTO, May 24, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
May 10, 2017 15:17 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces FDA Final Approval of Generic Seroquel XR®

TORONTO, May 10, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
April 18, 2017 18:15 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Reports Director Election Results

TORONTO, April 18, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...